Stock Price Prediction

AURA stock has a bullish outlook with a price target of $23, supported by promising clinical data for its drug candidate bel-sar, which demonstrates improved tumor control and vision preservation in primary choroidal melanoma patients. However, insider sentiment is negative, with consistent insider selling over the past six months, which could indicate caution. The stock closed at $7.85 on January 31, 2025, suggesting significant upside potential if the clinical developments materialize.

The bear's view on AURA stock is cautious due to insider selling and mixed institutional sentiment. Recent insider activity shows consistent selling, with no purchases in six months, raising concerns about confidence in the stock's future. Despite a $23 price target from analysts based on promising clinical data, the insider sentiment suggests potential downside risks.